HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

Accepted/In Press date: 20 February 2022

Published date: 7 April 2022

Additional Information: Funding Information: Funding was provided by Cancer Research UK, programme grant awarded to M.S.C., J.C.S., S.M.T and S.A.B. (Award number: A24721) and the United Kingdom National Centre for the Replacement, Refinement and Reduction of Animals in Research, CRACKIT Programme grant awarded to M.J.G., S.A.B. and A.R. (Award number: NC3Rs 15402–106217) and Cancer Research UK and Experimental Cancer Centre awards C328/A25139 and C24563/A25171. TM, RL, KTJM and JL were funded through Cancer Research UK studentship award C328/A25169. TM was also funded through the Cancer Immunology Talent fund. RJS was funded by BBSRC iCASE award with Promega. Funding Information: We would like to thank the members of the Antibody and Vaccine group for useful discussions and the pre-clinical unit staff for animal husbandry and assistance. ATAC-seq samples were prepared by Victoria Gernedl in the Bock lab and bioinformatically processed by Bekir Erg?ner. The sequencing was performed by the Biomedical Sequencing Facility at the Center for Molecular Medicine, Vienna. We would like to thank Dr. Francesco Forconi, Dr. N Kathleen Potter, Dr. Ian Tracy and Mrs. Isla Henderson (University of Southampton, The Human Tissue Bank) for provision of CLL samples. We would like to thank Ms. Deborah Donovan (Southampton NHS Trust) for assisting us in the use of the ABL 835 FLEX analyzer, in order to measure metabolites and electrolytes in cell culture supernatants. We would like to thank Prof J and D Mann (University of Newcastle) for insightful initial discussions. We would like to thank Dr Zo? S Walters and Dr Ian Tracy for their expertise on ChIP assays. We would like to thank CRUK Southampton Centre Bioinformatics core facility for supporting this work. Finally, we would like to acknowledge Dr Charles Tilley and Dr Janlyn Falconer for assistance with pathology and provision of primary tumor clinical samples, respectively. Funding Information: A.R. receives funding from BioInvent International. Research by R.I.C is supported by use of equipment to measure body composition provided by SECA through a model industry collaborative agreement (mICA) with University Hospital Southampton. M.J.G previously acted as a consultant to a number of biotech companies and receives institutional payments and royalties from antibody patents and licenses. J.C.S has received funding from Roche. S.A.B acts as a consultant for a number of biotech companies and has received institutional support for grants and patents from BioInvent. M.S.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent International and has received research funding from BioInvent, GSK, UCB, iTeos, and Roche. Publisher Copyright: © 2022, The Author(s).

Keywords: Animals, Antibodies, Monoclonal/pharmacology, Humans, Hypoxia/metabolism, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell/metabolism, Macrophages/metabolism, Mice, Receptors, IgG/genetics, Tumor Microenvironment

Local EPrints ID: 456881

URI: http://eprints.soton.ac.uk/id/eprint/456881

DOI: doi:10.1186/s13046-022-02294-5

ISSN: 0392-9078

PURE UUID: 3df779fe-a7e4-4ac7-b4e2-fa259a7f40b1

ORCID for Kri T J Müller: orcid.org/0000-0001-5674-6125

ORCID for Sofia Macari: orcid.org/0000-0002-6506-4051

ORCID for Robert J Oldham: orcid.org/0000-0002-8007-1145

ORCID for Ali Roghanian: orcid.org/0000-0003-1316-4218

ORCID for Jonathan C Strefford: orcid.org/0000-0002-0972-2881

ORCID for Stephen A Beers: orcid.org/0000-0002-3765-3342

ORCID for Mark S Cragg: orcid.org/0000-0003-2077-089X

Date deposited: 16 May 2022 16:30

Last modified: 11 Jul 2024 01:57